MedPath

Effect of Non-invasive Multi Transducer Low-intensity Pulsed Ultrasound, SX-1001, on Clinical Symptoms in Buerger Disease with Critical Limb Ischemia: A Multicentre, Double-blind, Parallel Randomized Clinical Trial

Not Applicable
Recruiting
Conditions
Buerger disease
Registration Number
JPRN-UMIN000014757
Lead Sponsor
ippon Sigmax Co.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

• Planned major amputation during study period • Possibility of successful by-pass surgery or catheter treatment on the index leg • Applicability of by-pass surgery or catheter treatment on the index leg • Active malignant disease, severe malfunction of liver or kidney ng the forefoot evidenced by imaging (radiography) • Not expected to survive more than 12 months, in the opinion of a principal investigator of the study site • A history of malignant disease or previous or present history of cardiac infarction or stroke within 3 months before recruitment. • Cardiovascular diseases of New York Heart Association (NYHA) class III or IV or active angina • Women present or planned pregnant during the study period • Previous treatment with other investigational clinical trial within 6 months before recruitment • Heavy second-hand tobacco smoke or patients excluded by the opinion of the principal investigator of the study site

Study & Design

Study Type
Interventional,observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rest pain intensity change on visual analog scale from base line to 24th week
Secondary Outcome Measures
NameTimeMethod
Change of rest pain intensity on visual analog scale from base line to 12th week, change of transcutaneous oxygen pressure (TcPO2), skin perfusion pressure (SPP), ankle brachial pressure index (ABI), toe brachial pressure index (TBI) or walking distance from base line to 12th and 24th week, and change of symptoms relating burger disease in the study period of 24 weeks
© Copyright 2025. All Rights Reserved by MedPath